ImmunityBio Q3 2026 Results: Net Loss of $185M, Loss Widens
ImmunityBio reported total assets of $609.4 million as of September 30, 2026, an increase from $501.9 million at year-end 2025, driven primarily by a rise in marketable securities. The company maintains a significant stockholders' deficit and continues to operate as a large accelerated filer following the commercial launch of its approved product, ANKTIVA.
- Key figure
- Net loss $185M